Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Blood Cancer, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2008 |
| End Date: | March 2011 |
Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer
to study in the laboratory may help doctors find better ways to treat the cancer.
PURPOSE: This research study is looking at natural killer cells in bone marrow and blood
samples from patients with hematologic cancer and from patients who do not have cancer.
to study in the laboratory may help doctors find better ways to treat the cancer.
PURPOSE: This research study is looking at natural killer cells in bone marrow and blood
samples from patients with hematologic cancer and from patients who do not have cancer.
OBJECTIVES:
- To collect normal and malignant cells in bone marrow and peripheral blood samples from
patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous
leukemia, or multiple myeloma and from patients with no malignancy to use as target
cells in cytotoxicity assays.
- To collect information about HLA type and immunophenotype of malignant cells as
determined by clinical flow cytometry.
OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as
target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells
as the effector cells, to determine whether N-NK cells are capable of killing malignant
cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine
which NK cell receptors are responsible for malignant cell recognition and killing.
Information about HLA type and immunophenotype of the malignant cells is collected from the
patient's medical record.
- To collect normal and malignant cells in bone marrow and peripheral blood samples from
patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous
leukemia, or multiple myeloma and from patients with no malignancy to use as target
cells in cytotoxicity assays.
- To collect information about HLA type and immunophenotype of malignant cells as
determined by clinical flow cytometry.
OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as
target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells
as the effector cells, to determine whether N-NK cells are capable of killing malignant
cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine
which NK cell receptors are responsible for malignant cell recognition and killing.
Information about HLA type and immunophenotype of the malignant cells is collected from the
patient's medical record.
DISEASE CHARACTERISTICS:
- Meets one of the following criteria:
- No evidence of malignancy
- Diagnosis of one of the following:
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Chronic myelogenous leukemia
- Multiple myeloma
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
We found this trial at
1
site
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center We all know...
Click here to add this to my saved trials
